



Aprecia Pharmaceuticals Company

Aprecia seeks to transform the way people take medicine. By applying three-dimensional (3D) printing technology and formulation science to frequently-prescribed high-dose medications, Aprecia seeks to fill a need for patients who may struggle to take their current medicines. The company is the first to receive approval from the U.S. Food and Drug Administration (FDA) to manufacture a pharmaceutical product using its proprietary 3D printing technology platform.

Fast Facts

- Specialty pharmaceutical company founded in 2003.
- Headquartered in Blue Ash, Ohio, with manufacturing facilities in Blue Ash and East Windsor, N.J.
- Currently investing \$25 million in its 190,000-square-foot Blue Ash manufacturing facility, which is projected to bring 150 new jobs to Blue Ash, adding \$13.45 million in additional annual payroll by December 31, 2017.
- Privately owned, with Prasco Laboratories and its parent company, Scion Companies holding controlling interest.

Aprecia's Proprietary 3D Printing Technology

- Aprecia's 3D printing technology platform is a groundbreaking advance that combines 3D printing with formulation science to produce a porous formulation that rapidly disintegrates with a sip of liquid.
- It is designed to enable the delivery of high-dose loads, up to 1,000 mg in a single dose.

Product Pipeline

- The company has patents in place for its proprietary technology platform, and has patents pending for its full-scale equipment and initial pipeline products with prospective term beyond 2030.
- Aprecia plans to introduce multiple new products utilizing its proprietary technology platform in the coming years, focusing first on the central nervous system therapeutic area, where there is a need for medicines that are easy to take.

For more information, visit www.aprecia.com.